SHILPAMED
Shilpa Medicare Limited (SHILPAMED) Stock Analysis
Shilpa Medicare Limited manufactures oncology APIs, formulations, and biosimilars for regulated markets. It develops complex injectables and specialty drugs with facilities approved for US and EU supply. The company focuses on high-value pharmaceutical segments. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹962.10
-10.18% 1W | +173.00% 52W
Market Cap
18.8k CR
P/E Ratio
67.9
52W High
₹1095
52W Low
₹259.5
Div. Yield
0.06%
Beta
0.3
50 DMA
₹931.7
200 DMA
₹558.1
Profit Margin
17.7%
Inst. Own.
10.9%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 260 | 313 | 287 | 292 | 293 | 344 | 319 | 331 | 321 | 370 | 410 | 437 | 466 |
| Expenses | 214 | 255 | 222 | 222 | 222 | 258 | 239 | 252 | 231 | 262 | 296 | 317 | 330 |
| Operating Profit | 46 | 58 | 65 | 70 | 70 | 86 | 81 | 79 | 91 | 108 | 114 | 120 | 136 |
| OPM % | 18% | 19% | 23% | 24% | 24% | 25% | 25% | 24% | 28% | 29% | 28% | 27% | 29% |
| Other Income | 2 | 2 | 2 | 9 | 10 | 5 | 2 | -21 | 6 | 2 | -13 | 45 | 9 |
| Interest | 18 | 23 | 26 | 24 | 24 | 26 | 12 | 14 | 19 | 16 | 11 | 14 | 12 |
| Depreciation | 27 | 28 | 27 | 27 | 27 | 28 | 29 | 29 | 29 | 30 | 30 | 31 | 35 |
| Profit before tax | 3 | 9 | 14 | 28 | 29 | 37 | 42 | 15 | 50 | 64 | 61 | 120 | 98 |
| Tax % | 64% | 83% | 67% | 12% | 51% | 51% | 24% | 5% | 5% | 32% | 27% | 10% | -3% |
| Net Profit | 1 | 2 | 5 | 24 | 14 | 18 | 32 | 15 | 47 | 44 | 45 | 108 | 101 |
| EPS in Rs | 0.07 | 0.09 | 0.26 | 1.41 | 0.72 | 0.92 | 1.62 | 0.74 | 2.40 | 2.25 | 2.28 | 5.51 | 5.16 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 614 | 719 | 779 | 789 | 733 | 908 | 899 | 1,141 | 1,046 | 1,146 | 1,281 | 1,535 | 1,683 |
| Expenses | 485 | 566 | 614 | 634 | 585 | 688 | 718 | 940 | 947 | 907 | 962 | 1,100 | 1,204 |
| Operating Profit | 129 | 153 | 165 | 155 | 148 | 219 | 181 | 202 | 99 | 239 | 319 | 435 | 479 |
| OPM % | 21% | 21% | 21% | 20% | 20% | 24% | 20% | 18% | 9% | 21% | 25% | 28% | 28% |
| Other Income | 5 | 5 | 15 | 22 | 33 | 17 | 90 | 21 | 17 | 15 | -8 | 39 | 43 |
| Interest | 4 | 7 | 3 | 3 | 4 | 5 | 22 | 41 | 59 | 92 | 76 | 59 | 52 |
| Depreciation | 21 | 29 | 31 | 37 | 42 | 44 | 54 | 80 | 96 | 108 | 113 | 120 | 126 |
| Profit before tax | 108 | 122 | 146 | 137 | 136 | 188 | 195 | 102 | -38 | 54 | 122 | 295 | 344 |
| Tax % | 33% | 19% | 29% | 25% | 19% | 18% | 25% | 41% | -19% | 41% | 36% | 18% | |
| Net Profit | 73 | 99 | 104 | 103 | 110 | 155 | 146 | 61 | -31 | 32 | 78 | 243 | 297 |
| EPS in Rs | 4.78 | 6.73 | 6.71 | 6.45 | 6.88 | 9.57 | 9.06 | 3.49 | -1.87 | 1.84 | 4.00 | 12.44 | 15.20 |
| Dividend Payout % | 6% | 4% | 4% | 5% | 7% | 6% | 6% | 16% | 0% | 0% | 12% | 5% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 14.0% | 11.0% | 8.0% |
| Profit CAGR | 107.0% | 17.0% | 8.0% |
Shareholding Pattern
Promoters44.23%
FIIs10.92%
DIIs7.67%
Public37.18%
Promoters40.13%
FIIs10.97%
DIIs8.34%
Public40.56%
Promoters40.13%
FIIs11.07%
DIIs8.58%
Public40.21%
Promoters40.13%
FIIs11.39%
DIIs8.05%
Public40.42%
Promoters40.13%
FIIs12.11%
DIIs8.26%
Public39.49%
Promoters50.01%
FIIs13.73%
DIIs0.54%
Public35.72%
Promoters50.01%
FIIs5.63%
DIIs1.65%
Public42.71%
Promoters44.23%
FIIs10.97%
DIIs7.55%
Public37.25%
Promoters40.13%
FIIs11.07%
DIIs8.58%
Public40.21%
Promoters40.13%
FIIs12.11%
DIIs8.26%
Public39.49%
SHILPAMED
Holdings Analysis
Key strengths & risk signals
66
Overall
52
Fundamental
81
Technical
Risks (1)
Cannot calculate PEG - insufficient growth data.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (917.4) is above 200-day average (551.3) - positive signal.
EXCELLENT YEAR! Stock gained 189.4% in the last year.
STRONG! Trading at 85.5% of 52W range - near yearly highs.
Fundamental & Technical Analysis
66Overall
52Fundamental
81Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 13.8% (GOOD, 11/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
6/10
GOOD EFFICIENCY! 17.7% profit margin - above average profitability.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.06% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 39.36% public ownership - moderate retail influence.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (931.7) is above 200-day average (558.1) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (962.1) is above both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 173.0% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 1,072,554 vs down days: 796,142. Ratio: 1.35x
RSI
3/5
NEUTRAL! RSI at 46.4 - balanced momentum.
52W Range
5/5
STRONG! Trading at 84.1% of 52W range - near yearly highs.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -10.2% (1 week), 0.1% (1 month), 50.8% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
SHILPAMED
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-10 | Concall PDF | |
| Q4FY262026-05-26 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262025-11-19 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SHILPAMED | ₹962.10 | 67.9 | 17.7% | 13.8% | – | +173.0% | 66 | BREAKDOWN | +115.1% | -6.4% | +44.9% | +6.6% |
| CAPLIPOINT | ₹2,338.20 | 26.8 | 29.1% | 14.3% | 19.4% | +19.8% | 76 | BREAKDOWN | +15.8% | +4.0% | +19.6% | +1.7% |
| COHANCE | ₹445.60 | 163.2 | 5.0% | 18.3% | -24.2% | -48.9% | 58 | CONSOLIDATING DOWN | -149.3% | -223.0% | -23.1% | -31.8% |
| ALIVUS | ₹1,348.00 | 27.5 | 23.3% | 6.9% | 6.5% | +44.0% | 70 | APPROACHING RESISTANCE | +31.8% | -1.6% | +6.4% | -7.1% |
| ERIS | ₹1,149.60 | 24.5 | 20.0% | 23.3% | 17.5% | -27.0% | 64 | BREAKDOWN | +20.7% | -49.4% | +12.6% | +15.5% |
| APLLTD | ₹792.50 | 22.7 | 8.9% | 9.5% | 25.4% | -14.0% | 74 | CONSOLIDATING UP | +12.1% | -14.6% | +25.7% | +16.4% |
| JUBLPHARMA | ₹938.90 | 42.4 | 4.1% | 9.8% | – | -12.4% | 54 | BREAKDOWN | -45.1% | -52.7% | +18.2% | -2.2% |
| ASTRAZEN | ₹5,950.50 | 87.7 | 7.0% | 31.3% | 23.6% | -35.3% | 56 | APPROACHING SUPPORT | -32.1% | -15.6% | +29.7% | +18.0% |
Data from TradeAlone · Updated daily
SHILPAMED News
Shilpa Medicare Limited (NSE: Shilpamed) Gets Final Approval for Oeristm2026-09-11Shilpa Medicare Limited (NSE: SHILPAMED) breaks out, gains 5% intraday2026-08-10Shilpa Medicare Limited (SHILPAMED) breaks out, gains 5% intraday2026-08-06Shilpa Medicare Limited (SHILPAMED) breaks out, gains 11% intraday2026-08-05Shilpa Medicare Limited (shilpamed) 1qfy27 Earnings: Revenue Up 43%, Ebitda Grows 42%2026-08-05Shilpa Medicare Limited (SHILPAMED) gains 5% intraday, nears resistance2026-07-09Shilpa Medicare Limited (NSE: SHILPAMED) extends gains by 5% intraday2026-07-02Shilpa Medicare Limited (SHILPAMED) gives up ground after breakout, falls 5% intraday2026-07-01Shilpa Medicare Limited (NSE: SHILPAMED) breaks out, gains 5% intraday2026-06-30Shilpa Medicare Limited (NSE: Shilpamed) Expands Partnership with Orion Corporation for Nivolumab Biosimilar2026-06-30Shilpa Medicare Limited (shilpamed) Commissions Advanced ADC Drug Substance GMP Facility2026-06-24Shilpa Medicare Limited (NSE: SHILPAMED) breaks out, moves up 5% intraday2026-06-23Shilpa Medicare Limited Acquires 30.4% Stake in Gate2brain to Advance Brain Cancer Therapy2026-06-03Shilpa Medicare Limited (shilpamed) Q4 FY26: Revenue Up 30%, Ebitda Surges 40%2026-05-22
